NCT06436170

Brief Summary

Pseudophakic cystoid macular edema (PCME), also known as Irvine-Gass syndrome (IGS), is an accumulation of fluid in the macula that occurs after cataract surgery, with an early or late presentation (cut-off 3 months) . It is the most common cause of decreased vision after uneventful phacoemulsification, with a rare incidence of 0.1-2.35% for clinically significant PCME . Macular edema in IGS can be diagnosed and classified by optical coherence tomography (OCT), which enables its morphologic assessment. Fluorescein angiography (FA) is the gold standard to perform differential diagnosis for macular edema. To date, OCT angiography (OCTA) has been proposed to study various retinal vascular diseases. In contrast to FA, OCTA is able to visualize Radial peripapillary vessel density (RCP). The aim of this study was to investigate abnormalities in the vascular network of the optic nerve head in patients with IGS compared to healthy eyes, using OCT-A

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 29, 2024

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

May 21, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 30, 2024

Completed
Last Updated

May 30, 2024

Status Verified

May 1, 2024

Enrollment Period

6 months

First QC Date

May 21, 2024

Last Update Submit

May 28, 2024

Conditions

Keywords

OCTA;RPC; IGS;PCME

Outcome Measures

Primary Outcomes (1)

  • the role of OCTA in diagnosis of IGS

    To evaluate the vascolarization of RPC in IGS

    10 months

Study Arms (2)

30 patiens with IGS mean age 70 ±6

Diagnostic Test: OCTA

30 healthy controls mean age 70 ±5

Diagnostic Test: OCTA

Interventions

OCTADIAGNOSTIC_TEST

OCTA is a non invasive diagnostic technique to visualize RPC

30 healthy controls mean age 70 ±530 patiens with IGS mean age 70 ±6

Eligibility Criteria

Age58 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with a diagnosis of PCME following phacoemulsification, addressed to our Unit, were enrolled in the study. The diagnostic criteria for PCME were: 1) vision loss in the operated eye within 3 months after surgery in patients with acute PCME and after 3 months for patients with chronic PCME; 2) changes on B-scan structural OCT with intraretinal cystoid spaces and central macular thickness (CMT) of at least 300 micron; 3) leakage and pooling of dye in macular cystoid spaces and late hyperfluorescence of the optic nerve head on FA. Clinical suspicion of PCME was confirmed using FA and structural OCT.

You may qualify if:

  • Clinical diagnosis of PCME Cataract surgery

You may not qualify if:

  • diabetes vein occlusion uveitis vasculitis age-related macular degeneration hereditary macular dystrophy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Federico II of Naples

Naples, 80121, Italy

Location

MeSH Terms

Conditions

CataractMacular Edema

Condition Hierarchy (Ancestors)

Lens DiseasesEye DiseasesMacular DegenerationRetinal DegenerationRetinal Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 21, 2024

First Posted

May 30, 2024

Study Start

July 1, 2023

Primary Completion

December 30, 2023

Study Completion

April 29, 2024

Last Updated

May 30, 2024

Record last verified: 2024-05

Locations